Alvotech (ALVO) Notes Payables (2022 - 2026)

Alvotech's (ALVO) quarterly Notes Payables came in at $22.5 million in Q2 2023, up 12.79% on a QoQ basis from $19.9 million in Q4 2022.

Alvotech (ALVO) Notes Payables (2022 - 2026) Analysis & Trends

Alvotech (ALVO) has 2 years of Notes Payables data on file, last reported at $22.5 million in Q2 2023.

Quarterly Notes Payables changed N/A year-over-year to $22.5 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $22.5 million (changed N/A YoY) and the FY2022 annual result came in at $19.9 million, changed N/A from the prior year.
Notes Payables grew to $22.5 million in Q2 2023, from $19.9 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $22.5 million in Q2 2023 to a low of $19.9 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Alvotech	1.26 Bn	1.26 Bn	5.09 Mn

Download Data